title: Single dose palonosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regimen in Hodgkin Lymphoma patients.
abstract: To evaluate the efficacy of a new agent, palonosetron, in Hodgkin Lymphoma patients treated with ABVD regimen. Complete response during the overall phase of the first ABVD cycle, was the primary endpoint. Secondary end points were: emesis-free patients and use of rescue medication during the acute and overall phases. From January 2008 to February 2009 36 patients were enrolled. The primary endpoint (CR 0-120 h) was achieved by 55.6% patients. In conclusion our study demonstrated that a single dose of palonosetron plus a single dose of dexamethasone was effective in preventing CINV in patients treated with ABVD regimen.
authors.affiliation: Haematology Department, Azienda Ospedaliero Universitaria Careggi, Largo Brambilla, 3 50139 Firenze, Italy. luigi.rigacci@unifi.it
authors.forename: Luigi
authors.initials: L
authors.lastname: Rigacci
authors.forename: Carla
authors.initials: C
authors.lastname: Landi
authors.forename: Jean Pierre
authors.initials: JP
authors.lastname: Caruso
authors.forename: Benedetta
authors.initials: B
authors.lastname: Puccini
authors.forename: Renato
authors.initials: R
authors.lastname: Alterini
authors.forename: Valentina
authors.initials: V
authors.lastname: Carrai
authors.forename: Tania
authors.initials: T
authors.lastname: Perrone
authors.forename: Alberto
authors.initials: A
authors.lastname: Bosi
mesh_terms: D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001761:Bleomycin / Q000009:adverse effects; D003606:Dacarbazine / Q000009:adverse effects; D003907:Dexamethasone / Q000008:administration & dosage*; D004317:Doxorubicin / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D007546:Isoquinolines / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D000077924:Palonosetron; D011446:Prospective Studies; D011812:Quinuclidines / Q000008:administration & dosage*; D012702:Serotonin Antagonists / Q000008:administration & dosage; D016896:Treatment Outcome; D014747:Vinblastine / Q000009:adverse effects; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*; D055815:Young Adult
chemical_list: D000932:Antiemetics; D007546:Isoquinolines; D011812:Quinuclidines; D012702:Serotonin Antagonists; D001761:Bleomycin; D000077924:Palonosetron; D014747:Vinblastine; D003606:Dacarbazine; D003907:Dexamethasone; D004317:Doxorubicin